• Mashup Score: 0

    The JHLT Digital Media Editors explore two manuscripts from the August issue of The Journal of Heart and Lung Transplantation—the first on immunosuppression in pediatric heart transplantation, and the second TA-NRP in DCD lung transplantation. Digital Media Editor Van-Khue Ton, MD, heart failure and transplant cardiologist at Massachusetts General Hospital, hosts this episode.   First, hear from senior author Steven C. Greenway, MSc, MD, on his team’s study “.” Dr. Greenway shares his journey from enzyme biochemistry in mollusks, snails, and frogs to pediatric cardiology, then outlines the results of the paper.   The study queried the Pediatric Heart Transplant Society’s registry to determine the efficacy and safety of monotherapy immunosuppression. The results showed better graft survival and less coronary allograft vasculopathy in the monotherapy group, even after adjusted for age at transplant, sex, neonatal transplant, infection, PTLD, and etiology of cardiomyopathy. Dr. Greenway a

    Tweet Tweets with this article
    • Have you listened to the August #JHLTThePodcast yet? Great stuff on #immunosuppression in peds #HeartTx and TA-NRP on early outcomes in #DCD #LungTx from Steven C. Greenway and @JadMalasMD! Check the thread🧵below for details on the studies, and listen at https://t.co/pVodmrbHMV https://t.co/N7EiMw2ZzB

  • Mashup Score: 1

    Thoracoabdominal normothermic regional perfusion has emerged as an alternative method to procure donation after circulatory death (DCD) hearts, but its impact on concomitantly procured lung allografts remains unclear. The United Network for Organ Sharing database identified 627 DCD donors whose hearts were procured (211 in situ perfused, 416 directly procured) between December 2019 to December 2022. Lung utilization rates were 14.9% (63/422) for in situ perfused donors and 13.8% (115/832) for directly procured donors (p = 0.80).

    Tweet Tweets with this article
    • 2⃣ First author @malas_jad joins from @CedarsSinai to discuss the impact of TA-NRP on early outcomes in #DCD #LungTx. Dr. Malas shares interesting findings from the study, plus details on what might be needed to further evaluate this procurement technique: https://t.co/uT1QOLQNth

  • Mashup Score: 2

    The JHLT Digital Media Editors explore two manuscripts from the July issue of The Journal of Heart and Lung Transplantation—one on heart transplantation and one on lung transplantation. Digital Media Editor Marty C. Tam, MD, Assistant Professor at the University of Michigan, hosts this episode.   First, hear from co-first author Kevin Chen, MD, on his team’s study “,” which comes from Cedars-Sinai. The study looks into the results of DCD organ donation depending on the technique used at procurement, mainly comparing ex-situ normothermic organ perfusion with thoracoabdominal normothermic regional perfusion (TA-NRP).   Digital Media Editors David Schibilsky, MD, and Van-Khue Ton, MD, have questions on the relationship between DCD liver and kidney procurement and heart procurement strategies, why TA-NRP livers and kidneys might differ, and the lower incidence of delayed graft function in DCD kidney transplants with TA-NRP. Dr. Chen also shares some thoughts about how this work might be in

    Tweet Tweets with this article
    • Have you listened to the July #JHLTThePodcast yet? Some good stuff on #DCD hearts and #LungTx #frailty from @KevinQ_Chen and @jsinger0 this month! Check the thread🧵below for details on the studies, and listen on your favorite podcatcher (or at https://t.co/tTZx5okVHL). https://t.co/S72duOMF0F

  • Mashup Score: 2

    Accept Cookies & Privacy Policy? This website uses cookies to ensure the best possible web experience. By continuing and using the site, you consent to the use of cookies. If you wish to disable them or to learn more about how we use cookies, please view our Cookies Policy. …

    Tweet Tweets with this article
    • Are you or a colleague doing cutting-edge work on #biomarkers, #BOS, or #ddcfDNA?Don't miss the opportunity to apply for NEW 2023 #ISHLTResearchGrants. 📅You have until the end of Sep to apply! 🔗https://t.co/Q3zlmjTWpf #ISHLT #HeartTx #LungTx https://t.co/hOIi2pp8nN

  • Mashup Score: 0

    Accept Cookies & Privacy Policy? This website uses cookies to ensure the best possible web experience. By continuing and using the site, you consent to the use of cookies. If you wish to disable them or to learn more about how we use cookies, please view our Cookies Policy. …

    Tweet Tweets with this article
    • REMINDER: Applications are open for NEW 2023 #ISHLTResearchGrants. If you or a colleague are doing cutting-edge work on #biomarkers, #BOS, or #ddcfDNA, don't miss this opportunity. 📅You have until the end of Sep to apply! 🔗https://t.co/Q3zlmjTWpf #ISHLT #HeartTx #LungTx https://t.co/Gkd5hLB2aS

  • Mashup Score: 1

    Accept Cookies & Privacy Policy? This website uses cookies to ensure the best possible web experience. By continuing and using the site, you consent to the use of cookies. If you wish to disable them or to learn more about how we use cookies, please view our Cookies Policy. …

    Tweet Tweets with this article
    • REMINDER: Applications are open for NEW 2023 #ISHLTResearchGrants. If you or a colleague are doing cutting-edge work on #biomarkers, #BOS, or #ddcfDNA, don't miss this opportunity. 📅You have until the end of Sep to apply! 🔗https://t.co/xHHQRTq3hY #ISHLT #HeartTx #LungTx https://t.co/lnSG54RgxF

  • Mashup Score: 0

    After an inspiring opening plenary, “Back to the Future of AMR,” co-chaired by Glen Westall, FRACP, PhD from Alfred Hospital in Melbourne, and Meghan Aversa, MD, from the University of Toronto, engaged attendees seeking an update about the current state of knowledge on the detection, pathogenesis, and treatment of antibody-mediated rejection (AMR). Jake Natalini, MD, MSCE, from NYU Langdon…

    Tweet Tweets with this article
    • The Lung team - @dralourdeschac1 and @RAKlingbeilDNP - spent Saturday at #ISHLT2023 covering COVID in #LungTx, improvements in #EVLP, #LungTx rejection, and advances in fungal biology. https://t.co/fPlU2OcnkN https://t.co/dsU7Wl4M5L

  • Mashup Score: 1

    This website uses cookies to ensure the best possible web experience. By continuing and using the site, you consent to the use of cookies. If you wish to disable them or to learn more about how we use cookies, please view our Cookies Policy. NEW ISHLT Multimodality Research on Heart Transplant Patient Care…

    Tweet Tweets with this article
    • Now accepting applications for NEW 2023 #ISHLTResearchGrants on multimodal #HeartTx surveillance, noninvasive biomarkers in #LungTx, and early detection of #BOS. You have until the end of September to apply! 🔗https://t.co/xHHQRTqB7w #ISHLT #ResearchGrant #GrantApplications https://t.co/7QWUhfANk6

  • Mashup Score: 6

    This website uses cookies to ensure the best possible web experience. By continuing and using the site, you consent to the use of cookies. If you wish to disable them or to learn more about how we use cookies, please view our Cookies Policy.   Modernizing Your Transplant Program with an Integrated…

    Tweet Tweets with this article
    • Join #ISHLT and Lung Bioengineering (LBE) on 1 June for a one-hour webinar where Matthew Bacchetta, MD from @VUMCtransplant will provide a first-hand account of how his program has grown through utilization of EVLP services. #LungTX Free to register: https://t.co/J7OhfRJpfI https://t.co/yHN802M2GX